ClinicalTrials.gg
TerminatedNCT02246920Updated Jun 8, 2023Results posted

Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuation vs. Flonase in Allergic Rhinitis Patients

A Phase 3 interventional study of Fluticasone propionate and Flonase® in Seasonal Allergic Rhinitis, sponsored by Teva Pharmaceuticals USA. Terminated at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-06-08.

Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Other

Why this study was terminated
Development Halted

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Mar 2014, registered Sep 2014).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,474
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing fluticasone in Rhinitis, Allergic, Seasonal — none open to participants now, none under way, none of them phase 3. Fluticasone · Rhinitis, Allergic, Seasonal.

Enrollment
3rd of 28
1,474 · median 326
Started
2014
with 1 other
Phase 3
14 of 28
none open now
Registered
25th of 28
by date
Lead sponsor
2 of 28
Teva Pharmaceuticals USA

Among the 28 studies testing fluticasone in Rhinitis, Allergic, Seasonal, this one is the 3rd largest by enrollment, is one of 2 that started in 2014, is one of 14 in phase 3, and was the 25th registered.

Rhinitis, Allergic, Seasonal

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

Browse Rhinitis, Allergic, Seasonal studies →

Open to participants now

None of the 28 studies testing fluticasone in Rhinitis, Allergic, Seasonal is open now. The open studies under Rhinitis, Allergic, Seasonal, anywhere →

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 28 studies testing fluticasone in Rhinitis, Allergic, Seasonal as a file.
02

Study summary

This double-blind, randomized, placebo-controlled, parallel group, multi-site study has been designed to compare the safety and efficacy of a generic Fluticasone propionate Nasal Spray, 50 mcg (Teva Pharmaceuticals USA) to the FDA Reference Listed Drug, Flonase® (fluticasone propionate) 50 mcg nasal spray (GlaxoSmithKline), in the relief of the signs and symptoms of Seasonal Allergic Rhinitis. Additionally, both the test and reference formulations will be tested for superiority against a placebo nasal spray.

03

Conditions studied

  • Seasonal Allergic Rhinitis

Keywords

  • Bioequivalence
  • Allergic Rhinitis
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or non-pregnant, non-lactating female 12 years or age or older.
  • Signed form, which meets all criteria of current FDA regulations. For patients under the age of majority in the state the study is being conducted (18 years in most states) the parent or legal guardian should sign the consent form and the child will be required to sign a patient "assent" form that will be written in such a way as to be understandable to a child.
  • If female and of , have a negative urine pregnancy test and is prepared to abstain from sexual intercourse or use a reliable method of during the study. In order for hormonal birth control to be considered a reliable method the patient must have been on their regimen for at least 28 days.
  • Documented positive allergic skin test, performed within the previous 12 months, to one or more of the allergens in season at the time the study is being conducted.
  • A minimum of two consecutive years of previous history of seasonal allergic rhinitis to the pollen/allergen in season at the time the study is being conducted.
  • A score of at least 6 on the reflective Total Nasal Symptom Score (rTNSS) and a minimum score of at least 2 for "nasal congestion" and a minimum score of at least 2 for one of the remaining 3 symptoms representing the 12 hours prior to the screening visit.
  • An average composite score of at least 6 on the reflective Total Nasal Symptom Score (rTNSS) and a minimum score of at least 2 for "nasal congestion" and a minimum score of at least 2 for one of the remaining 3 symptoms representing the last 3 days of the 7-day lead-in period before the randomization visit and the morning of the first day of the randomization visit.

Exclusion criteria

Exclusion Criteria:

  • Under 12 years of age.
  • Females who are pregnant, lactating, or likely to become pregnant during the study.
  • Negative or lack of documented skin allergen test (performed within the previous 12 months) to at least one of the allergens in season at the time of the study is being conducted. The results of all positive shin allergen tests should be reported.
  • Patients who suffer from chronic signs and symptoms of perennial allergic rhinitis (PAR) should be excluded from the study unless the Investigator assesses that the patient's current signs and symptoms are a clear exacerbation of Seasonal Allergic Rhinitis (SAR) rather than chronic PAR.
  • Patients who suffer only from perennial allergic rhinitis or seasonal allergic rhinitis to a different allergen that that in season at the time the study is conducted.
  • Previous history of less than 2 years of seasonal allergic rhinitis to the pollen/allergen in season at the time the study is being conducted.
  • A total score of less that 6 on the reflective Total Nasal Symptom Score (rTNSS) or a score of less than 2 for "nasal congestion" or a score of less than 2 for all 3 of the remaining symptoms.
  • History of asthma over the previous 2 years that required chronic therapy. Occasional acute or mild exercise induced asthma will be allowable on the condition that the treatment of the attacks is restricted to beta-agonists only.
  • Patients with nasal conditions, including infectious rhinitis, rhinitis medicamentosa, or atrophic rhinitis.
  • nasal deformity (e.g. significantly deformed septum, nasal polyps, or ulcers) or any recent nasal surgery or trauma that has not completely healed.
  • Sinus infection within the previous 30 days or history of re-occuring sinus infections.
  • Patient has started immunotherapy (including topical or desensitization therapy) or changed their dose of immunotherapy within 30 days of the first dose, or is likely to have to start immunotherapy, or change their current dose during the study.
  • Treatment for oral Candidiasis within 30 days of starting the study or a current Candidiasis infection.
  • Upper respiratory tract infection within the previous 30 days.
  • Patients with a history of tuberculosis.
  • Patients with the presence of glaucoma, cataracts, ocular herpes simplex, conjunctivitis, or other eye infection not related to the diagnosis of SAR within 14 days of enrollment.
  • The patient has had recent exposure (30 days) or was at risk of being exposed to chicken pox or measles.
  • Patients with any untreated fungal, bacterial, or systemic viral infections within the previous 30 days.
  • Use of any ophthalmic within 14 days or nasal, inhaled, or systemic steroids within 30 days of the study start.
  • Use of medications that significantly inhibit the cytochrome P450 subfamily enzyme .
  • Use of intranasal or systemic second-generation anti-histamines within 10 days of enrollment.
  • Use of intranasal cromolyn within 14 days of enrollment.
  • Use of intranasal or systemic first-generation anti-histamines, leukotriene receptor antagonists or other nasal decongestants within 3 days of enrollment.
  • Use of any tricyclic anti-depressant within 30 days of enrollment.
  • Patients with attention-deficit disorder being treated with methylphenidate containing products that have not been on a stable dosing regimen for at least the 30 previous days and who cannot remain on the same dosing regimen throughout the study.
  • Desensitization therapy to the seasonal allergen that is causing the patients allergic rhinitis within the previous 6 months.
  • Previous SAR and/or PAR that has proven unresponsive to steroid therapy.
  • Any known to fluticasone, other steroids, or any of the components of the study nasal sprays.
  • Significant history or current evidence of chronic infectious disease, system disorder, organ disorder, or other medical condition that in the Investigator's opinion would place the study patient at undue risk by participating, or could jeopardize the integrity of the study evaluations.
  • Receipt of any drug as part of a research study within 30 days prior to the first dose.
  • Planned travel outside of the local area for more than 2 consecutive days or 3 days in total, during the patient's participation in the study.
  • Previous participation in this study.
  • The patient has a history or non-compliance with medical regimens or treatment protocols in previous clinical studies.
  • The patient is a member of the study staff or a member of the family of the investigational study staff.
  • The patient currently smokes cigarettes, cigars, and/or pipes and is a heavy smoker (for example, on average more than 10 cigarettes per day).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,474 participants (actual)

Study arms

  • Experimental
    Investigational Test Product

    Fluticasone propionate Nasal Spray, 50 mcg/actuation; 200 mcg/day for 14 days

    Drug: Fluticasone propionate

  • Active comparator
    Reference Listed Drug

    Flonase® (fluticasone propionate) Nasal Spray, 50 mcg/actuation; 200 mcg/day for 14 days

    Drug: Flonase®

  • Placebo comparator
    Placebo

    Saline Placebo Nasal Spray; 4 total sprays/day for 14 days

    Drug: Placebo

Interventions

  • 50 mcg/actuation Nasal Spray

  • 50 mcg/actuation Nasal Spray

    Also known as: Fluticasone propionate (generic name)

  • DrugPlacebo

    Inactive Nasal Spray

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Average AM/PM Reflective Total Nasal Symptom Score (rTNSS) Over Days 1 to 14.

    Total Nasal Symptom Score (TNSS) is defined as the sum of the patient-rated nasal symptom severity scores for the following four allergy symptoms: Runny Nose, Nasal Congestion, Itchy Nose, and Sneezing. The severity score for each symptom will be based on a 4-point scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe). The higher the score, the worse the symptoms of the 4 allergy categories are (runny nose, nasal congestions, itchy nose, and sneezing. The primary analysis for determining the therapeutic equivalence of the Test and Reference treatments will be based on each treatment's mean change from baseline for average rTNSS over the 2 week randomization treatment period. The Per-Protocol Population (PPP) will be used for the primary analysis of bioequivalence. The Modified Intent to Treat Population (mITT) will be used for Superiority Analysis.

    Time frame: 2 week treatment period: Day 0-14

Secondary outcomes

  1. Change From Baseline in Average Instantaneous Total Nasal Symptom Score (iTNSS) Over Days 1 to 14.

    Secondary efficacy analysis will evaluate the mean change from baseline in average iTNSS over the 2 week randomization treatment period. The Per-Protocol Population (PPP) will be used for the analysis of bioequivalence. Total Nasal Symptom Score (TNSS) is defined as the sum of the patient-rated nasal symptom severity scores for the following four allergy symptoms: Runny Nose, Nasal Congestion, Itchy Nose, and Sneezing. The severity score for each symptom will be based on a 4-point scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe). The higher the score, the worse the symptoms of the 4 allergy categories are (runny nose, nasal congestions, itchy nose, and sneezing.

    Time frame: 2 week treatment period: Day 0 to Day 14

Other outcomes

  1. Superiority to Placebo

    The primary analysis for determining the superiority of each active treatment over placebo will be based on each treatment's mean change from baseline for average rTNSS over the 2 week randomization treatment period. The modified Intent-to-Treat Population (mITT) will be used for the primary analysis of superiority. Total Nasal Symptom Score (TNSS) is defined as the sum of the patient-rated nasal symptom severity scores for the following four allergy symptoms: Runny Nose, Nasal Congestion, Itchy Nose, and Sneezing. The severity score for each symptom will be based on a 4-point scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe). The higher the score, the worse the symptoms of the 4 allergy categories are (runny nose, nasal congestions, itchy nose, and sneezing.

    Time frame: 2 week treatment period: Day 0 to Day 14

07

Results

Posted Jun 8, 2023

Participant flow

1474 subjects with SAR were enrolled into placebo run-in for the study.

Participant flow — Overall Study
MilestoneInvestigational Test ProductReference Listed DrugPlacebo
Started484460234
Completed477453231
Not completed773
Withdrew: Adverse event311
Withdrew: Lost to follow-up210
Withdrew: Protocol violation251
Withdrew: Withdrawal by subject001

Outcome measures

PrimaryChange From Baseline in Average AM/PM Reflective Total Nasal Symptom Score (rTNSS) Over Days 1 to 14.

Total Nasal Symptom Score (TNSS) is defined as the sum of the patient-rated nasal symptom severity scores for the following four allergy symptoms: Runny Nose, Nasal Congestion, Itchy Nose, and Sneezing. The severity score for each symptom will be based on a 4-point scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe). The higher the score, the worse the symptoms of the 4 allergy categories are (runny nose, nasal congestions, itchy nose, and sneezing. The primary analysis for determining the therapeutic equivalence of the Test and Reference treatments will be based on each treatment's mean change from baseline for average rTNSS over the 2 week randomization treatment period. The Per-Protocol Population (PPP) will be used for the primary analysis of bioequivalence. The Modified Intent to Treat Population (mITT) will be used for Superiority Analysis.

Time frame:
2 week treatment period: Day 0-14
Reported as:
Least squares mean · score on a scale
Change From Baseline in Average AM/PM Reflective Total Nasal Symptom Score (rTNSS) Over Days 1 to 14.
score on a scaleInvestigational Test ProductReference Listed DrugPlacebo
Change From Baseline in Average AM/PM Reflective Total Nasal Symptom Score (rTNSS) Over Days 1 to 14.-1.77 ± 0.11-1.57 ± 0.10-1.26 ± 0.15
Statistical analysis
  • Investigational Test Product vs Reference Listed Drug · T/r ls mean ratio: 108.09 · 90% CI 94.09 to 124.40
SecondaryChange From Baseline in Average Instantaneous Total Nasal Symptom Score (iTNSS) Over Days 1 to 14.

Secondary efficacy analysis will evaluate the mean change from baseline in average iTNSS over the 2 week randomization treatment period. The Per-Protocol Population (PPP) will be used for the analysis of bioequivalence. Total Nasal Symptom Score (TNSS) is defined as the sum of the patient-rated nasal symptom severity scores for the following four allergy symptoms: Runny Nose, Nasal Congestion, Itchy Nose, and Sneezing. The severity score for each symptom will be based on a 4-point scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe). The higher the score, the worse the symptoms of the 4 allergy categories are (runny nose, nasal congestions, itchy nose, and sneezing.

Time frame:
2 week treatment period: Day 0 to Day 14
Reported as:
Least squares mean · score on a scale
Change From Baseline in Average Instantaneous Total Nasal Symptom Score (iTNSS) Over Days 1 to 14.
score on a scaleInvestigational Test ProductReference Listed DrugPlacebo
Change From Baseline in Average Instantaneous Total Nasal Symptom Score (iTNSS) Over Days 1 to 14.-1.70 ± 0.11-1.53 ± 0.11-1.15 ± 0.15
Statistical analysis
  • Investigational Test Product vs Reference Listed Drug · T/r ls mean ratio: 107.00 · 90% CI 92.42 to 124.09
Other pre-specifiedSuperiority to Placebo

The primary analysis for determining the superiority of each active treatment over placebo will be based on each treatment's mean change from baseline for average rTNSS over the 2 week randomization treatment period. The modified Intent-to-Treat Population (mITT) will be used for the primary analysis of superiority. Total Nasal Symptom Score (TNSS) is defined as the sum of the patient-rated nasal symptom severity scores for the following four allergy symptoms: Runny Nose, Nasal Congestion, Itchy Nose, and Sneezing. The severity score for each symptom will be based on a 4-point scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe). The higher the score, the worse the symptoms of the 4 allergy categories are (runny nose, nasal congestions, itchy nose, and sneezing.

Time frame:
2 week treatment period: Day 0 to Day 14
Reported as:
Least squares mean · score on a scale
Superiority to Placebo
score on a scaleInvestigational Test ProductReference Listed DrugPlacebo
Superiority to Placebo-1.77 ± 0.11-1.57 ± 0.10-1.26 ± 0.15
Statistical analysis
  • Investigational Test Product vs Placebo · ANCOVA · p = 0.0028
  • Reference Listed Drug vs Placebo · ANCOVA · p = 0.0169

Adverse events

Collected over Adverse Events were collected from the time of ICF signature through the end of the study. Total duration 4-6 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Investigational Test Product0/484 (0%)2/484 (0.4%)0/484 (0%)
Reference Listed Drug0/460 (0%)0/460 (0%)0/460 (0%)
Placebo0/234 (0%)0/234 (0%)0/234 (0%)
Most frequent serious events
Most frequent serious events
EventInvestigational Test ProductReference Listed DrugPlacebo
ConcussionInjury, poisoning and procedural complications1/4840/4600/234
Rib FractureInjury, poisoning and procedural complications1/4840/4600/234
Conversion disorderPsychiatric disorders1/4840/4600/234
PneumothoraxRespiratory, thoracic and mediastinal disorders1/4840/4600/234

Baseline characteristics

Safety Population Randomized.

Age, Continuous
Age, Continuous(years)Investigational Test ProductReference Listed DrugPlaceboTotal
Mean39.3 (12 to 80)39.4 (12 to 76)39.1 (12 to 77)39.3 (12 to 80)
Sex: Female, Male
Sex: Female, Male(Participants)Investigational Test ProductReference Listed DrugPlaceboTotal
Female292274154720
Male19218680458
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Investigational Test ProductReference Listed DrugPlaceboTotal
American Indian or Alaska Native1012
Asian910625
Native Hawaiian or Other Pacific Islander2114
Black or African American11410864286
White357339160856
More than one race0000
Unknown or Not Reported1225
08

Study locations

1 site
  • Novum Pharmaceutical Research Services
    Pittsburgh, Pennsylvania 15206, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2014 to primary completion in Jul 2014, 4 months.

Results were first posted in Jun 2023, 8 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2014
First posted
Sep 23, 2014
StartActual
Mar 1, 2014
Primary completionActual
Jul 14, 2014
CompletionActual
Jul 14, 2014
Results first posted
Jun 8, 2023
Last update
Jun 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02246920
Responsible party
Sponsor
First posted
Sep 23, 2014
Start date
Mar 1, 2014
Primary completion
Jul 14, 2014
Completion
Jul 14, 2014
Results posted
Jun 8, 2023
Last update
Jun 8, 2023

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion